乐观
$10.01
情景价格
$15.300
+0.306 (+2.00%)收盘时
Phoenix Asia Holdings Ltd is an investment holding company mainly engaged in the substructure works business. The Company is mainly engaged in site formation, ground investigation and foundation works business as subcontractor. The Company also provides other construction services such as structural steelworks, advisory services and supervision services in substructure projects.
Currently, Phoenix Asia Holdings Ltd (PHOE) is not a strong buy due to its low RSI of 21.517, indicating oversold conditions, and a significant 5-day change of -15.33%. While the stock has potential upside due to the recent acquisition news, the negative earnings projections and declining gross margin (down to 4.57% in Q4 2026) present risks. The stock's recent performance shows a 1-year change of -9.09%, suggesting a lack of momentum. Investors should monitor for signs of recovery before committing capital.
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

ACEA Therapeutics to be Acquired by Phoenix Asia in $1 Billion Deal

Scilex Acquires ACEA Pharma for $1 Billion

SCILEX HOLDING CO - ACEA THERA TO ACQUIRE APPROXIMATELY 82% OF THE CONTINUING COMPANY AFTER CLOSURE

SCILEX HOLDING CO - PHOENIX TO CHANGE NAME TO ACEA PHARMA, INC. AND PLANS TO DEBUT ON NASDAQ

SCILEX HOLDING CO - ACEA THERA TO DIVEST ENTIRE STAKE IN ACEA PHARMA TO PHOENIX FOR $1 BILLION IN STOCK
Phoenix Asia Holdings Ltd is an investment holding company mainly engaged in the substructure works business. The Company is mainly engaged in site formation, ground investigation and foundation works business as subcontractor. The Company also provides other construction services such as structural steelworks, advisory services and supervision services in substructure projects. It operates in the Industrials sector.
Currently, Phoenix Asia Holdings Ltd (PHOE) is not a strong buy due to its low RSI of 21.517, indicating oversold conditions, and a significant 5-day change of -15.33%. While the stock has potential upside due to the recent acquisition news, the negative earnings projections and declining gross margin (down to 4.57% in Q4 2026) present risks. The stock's recent performance shows a 1-year change of -9.09%, suggesting a lack of momentum. Investors should monitor for signs of recovery before committing capital.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。